Background
Bicalutamide was developed as a second-generation nonsteroidal antiandrogen intended to improve on the tolerability of earlier agents such as flutamide. It entered clinical use in the 1990s and became widely adopted in urologic oncology for both combination androgen blockade and, at higher doses, as monotherapy. Multiple randomized trials evaluated bicalutamide across disease stages through the late 1990s and 2000s. Its role has narrowed as newer AR-targeted agents with superior efficacy in advanced and castration-resistant disease have entered practice; however, bicalutamide remains in use in selected settings and for cost or tolerability reasons.
Evidence snapshot
Bicalutamide is a well-studied nonsteroidal competitive antagonist of the androgen receptor. Randomized trials and pooled analyses have evaluated its efficacy in men with localized, locally advanced, and metastatic prostate cancer; benefit depends on disease stage and whether it is used as monotherapy or in combination with androgen-deprivation therapy.
At 150 mg daily, bicalutamide has been studied as an alternative to surgical or medical castration in selected men with localized or locally advanced disease. At 50 mg daily, it is used in combination with LHRH analogs for combined androgen blockade. Comparative survival effects vary by trial and disease stage.
Safety data show predictable endocrine adverse effects — gynecomastia, breast pain, decreased libido — as well as transaminase elevations. Severe hepatotoxicity is uncommon but documented; product labeling recommends baseline and periodic liver function monitoring.
Pharmacokinetics and bioavailability
Bicalutamide is well absorbed after oral administration and is highly plasma protein-bound. It undergoes extensive hepatic metabolism (primarily via oxidation and glucuronidation) and is eliminated in feces and urine. Its long elimination half-life (approximately 5–6 days at steady state) permits once-daily dosing. Steady-state plasma concentrations are reached after approximately four weeks of daily dosing. Hepatic impairment and CYP3A4-modulating drugs can meaningfully alter plasma exposure, which is why liver function monitoring and a medication review before initiation are standard practice.
Populations studied
Clinical trials and regulatory submissions have focused on men with localized, locally advanced, or metastatic prostate cancer. The primary evidence base comes from randomized controlled trials and pooled analyses comparing bicalutamide monotherapy (150 mg) or combination regimens (50 mg plus LHRH analog) with placebo or castration. Evidence for off-label use in transgender feminizing care is limited to observational studies and case series; that population requires specialist oversight and individualized monitoring.
Long-term safety and monitoring
Endocrine side effects — gynecomastia, breast pain, hot flashes, and sexual dysfunction — are common with antiandrogen monotherapy and are more frequent at 150 mg than 50 mg. Prophylactic breast irradiation or tamoxifen has been used to reduce gynecomastia in some protocols. Hepatotoxicity is uncommon but potentially serious: baseline liver function tests are recommended before starting, with periodic reassessment during therapy. INR must be monitored when bicalutamide is co-administered with warfarin. Long-term androgen pathway suppression also has implications for bone mineral density; clinicians managing patients on prolonged therapy should consider bone health assessment.
Compound variations
Bicalutamide 50 mg tablet
Standard lower-dose tablet used in combination with LHRH analogs for combined androgen blockade in advanced prostate cancer.
Common use case
Combined androgen blockade under oncologist supervision.
Dosage note
50 mg orally once daily; baseline and periodic liver function tests required.
Bicalutamide 150 mg tablet
Higher-dose tablet evaluated in clinical trials as monotherapy for localized or locally advanced prostate cancer.
Common use case
Monotherapy in selected patients per oncology specialist assessment.
Dosage note
150 mg orally once daily; higher rate of gynecomastia than the 50 mg dose; liver function monitoring required.
R-bicalutamide (active enantiomer)
The (R)-enantiomer is the pharmacologically active stereoisomer at the androgen receptor; studied separately in research contexts.
Common use case
Investigational and mechanistic research; not a standard clinical product.
Dosage note
Not available as a routine clinical formulation; dosing governed by trial protocols.
Compounded oral suspension
Pharmacy-compounded liquid formulation for patients unable to swallow tablets.
Common use case
Patients with swallowing difficulties where a compounded formulation is prescribed.
Dosage note
Bioavailability and stability can vary by compounding pharmacy; follow prescriber and dispensing pharmacy instructions.
Dosage and best practices
Dosage principles
- 50 mg orally once daily: standard dose in combination with LHRH analogs as part of combined androgen blockade (per product labeling and clinical practice guidelines).
- 150 mg orally once daily: dose evaluated in clinical trials as monotherapy for localized or locally advanced prostate cancer; use only under oncologist supervision.
- Obtain baseline liver function tests (ALT, AST, bilirubin) before starting therapy and monitor periodically; interrupt or discontinue for clinically significant transaminase elevations per label guidance.
Best practices
- Take bicalutamide once daily at a consistent time; tablets can be taken with or without food unless the prescriber directs otherwise.
- Obtain baseline liver enzymes before starting and report symptoms of liver injury promptly — jaundice, severe fatigue, dark urine, or upper abdominal pain.
- Review concomitant medications with a clinician or pharmacist before starting; bicalutamide interacts with warfarin and agents that alter CYP3A4 metabolism. INR should be monitored closely if anticoagulation with warfarin is ongoing.
Literature and references
Biology of progressive, castration-resistant prostate cancer: directed therapies targeting the androgen-receptor signaling axis
Journal of clinical oncology : official journal of the American Society of Clinical Oncology • 2005
Review describing mechanisms of AR-driven resistance and the rationale for AR antagonists in castration-resistant prostate cancer.
Bicalutamide (Casodex) — European public assessment report (EPAR)
European Medicines Agency • 2018
Regulatory assessment including clinical trial summaries, approved indications, dosing, and safety information for bicalutamide.
Bicalutamide prescribing information (Casodex) — FDA label
U.S. Food & Drug Administration • 2009
Product label with dosing regimens (50 mg and 150 mg), adverse reactions including hepatotoxicity, monitoring recommendations, and drug interactions including warfarin.
Bicalutamide compound summary
PubChem Compound Database, National Library of Medicine • 2023
Chemical and pharmacological data on bicalutamide including structure, synonyms, and pharmacokinetic properties.
Common questions
What is the difference between the 50 mg and 150 mg daily doses?
The 50 mg dose is used in combination with an LHRH analog for combined androgen blockade. The 150 mg dose has been studied as monotherapy in localized or locally advanced prostate cancer. The higher dose carries greater estrogenic side effects (particularly gynecomastia) because more circulating testosterone is available for peripheral aromatization. Dose selection is determined by disease stage and oncologist judgment.
Do I need liver tests while taking bicalutamide?
Yes. Baseline liver function tests (ALT, AST, bilirubin) are recommended before starting, with periodic monitoring during treatment. Bicalutamide is extensively metabolized by the liver, and rare but serious hepatotoxicity has been reported. Report jaundice, dark urine, severe fatigue, or right upper abdominal pain to your clinician promptly.
Can bicalutamide be used in transgender feminizing therapy?
Bicalutamide has been used off-label as an antiandrogen in some transgender care protocols. Evidence in this population consists primarily of observational data, and the hepatotoxicity risk warrants careful monitoring. Transgender hormone therapy should be managed by a clinician experienced in that field.
Will bicalutamide lower my testosterone levels?
No. Bicalutamide blocks the androgen receptor but does not suppress testosterone production. Circulating testosterone typically rises because reduced AR signaling diminishes negative feedback on the hypothalamic-pituitary-gonadal axis. When testosterone suppression is also needed, bicalutamide is combined with an LHRH analog or orchiectomy.